Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Ongoing Trials:

  • Liberty Asthma Expedition - The effect of Dupilumab on airway inflammation when added to usual asthma treatment
  • RASP - A trial of adjusting steroid dosing in severe asthma using inflammation markers compared to asthma symptoms and lung function
  • The AWARD study - The hospitalised acute wheezy adult with airways disease: studying the different characteristics and treatment responses
  • STARR - Studying the different characteristics of chronic obstructive pulmonary disease in primary care using near-patient testing and relating this to treatment responses during an acute exacerbation
  • STARR 2 - Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial
  • The effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with refractory eosinophilic asthma: A randomisaed, double blind, placebo controlled trial.
  • LASER - A multi-centre randomised, double blind, placebo-controlled, parallel group trial of the effectiveness of the nocturnal use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in adults with poorly-controlled, severe allergic asthma
  • Asthma Mepolizumab Trial
  • COPD Mepolizumab Trial
  • SoMOSA - Study of mechanisms of action of omalizumab in severe asthma.
  • Galathea - Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD exacerbations
  • NOVEL START - RCT of the efficacy and safety of an ICS/LABA reliver therapy regimen in asthma

Upcoming Trials:

  • A Multi-Center, Randomized, Double-Blind, Placebo-controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium- or high-dose ICS plus LABA with or without OCS
  • Hyperpolarized xenon gas MR imaging (Xe-129 MRI) of the lungs in Asthma